Literature DB >> 7507540

Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor.

F H Messerli1, R Ketelhut.   

Abstract

Left ventricular hypertrophy (LVH), an increase in the muscle mass of the left ventricle, has been identified as a powerful risk factor for future cardiovascular morbidity and mortality. The risk of acute myocardial infarction, congestive heart failure, sudden death, and other cardiovascular events increases sixfold to eightfold with the occurrence of LVH. The increase in myocardial mass lowers coronary reserve and enhances cardiac oxygen requirements, gives rise to ventricular ectopy, and impairs left ventricular filling and contractility. Hypertension, obesity, advanced age, valvular heart disease, and other pathologic disorders that cause an increase in the hemodynamic burden can lead to LVH. LVH and its sequelae can be reduced by specific antihypertensive therapy, but despite these promising findings, future epidemiologic studies are necessary to document the clinical benefits of a reduction in LVH.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7507540

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Digitized QT dispersion by the Valsalva maneuver in hypertensive patients.

Authors:  Hee-Jeoung Yoon; Seung-Won Jin; Jong-Min Lee; Woo-Seung Shin; Yong-Suk Oh; Man-Young Lee; Ki-Bae Seung; Tai-Ho Rho; Jae-Hyung Kim; Soon-Jo Hong; Kyu-Bo Choi
Journal:  Korean J Intern Med       Date:  2005-06       Impact factor: 2.884

2.  Effect of sodium tanshinone II A sulfonate on cardiac myocyte hypertrophy and its underlying mechanism.

Authors:  Jun Feng; Zhi Zheng
Journal:  Chin J Integr Med       Date:  2008-10-14       Impact factor: 1.978

3.  Left ventricular mass and the risk of sudden cardiac death: a population-based study.

Authors:  Jari A Laukkanen; Hassan Khan; Sudhir Kurl; Peter Willeit; Jouni Karppi; Kimmo Ronkainen; Emanuele Di Angelantonio
Journal:  J Am Heart Assoc       Date:  2014-11-05       Impact factor: 5.501

4.  Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial.

Authors:  Lili Wu; Yi Luan; Ya Li; Min Wang; Jialin He; Chongying Jin; Wenbin Zhang
Journal:  BMC Cardiovasc Disord       Date:  2020-06-05       Impact factor: 2.298

5.  QiShenYiQi pill activates autophagy to attenuate reactive myocardial fibrosis via the PI3K/AKT/mTOR pathway.

Authors:  Shichao Lv; Peng Yuan; Chunmiao Lu; Jianping Dong; Meng Li; Fan Qu; Yaping Zhu; Junping Zhang
Journal:  Aging (Albany NY)       Date:  2021-02-11       Impact factor: 5.682

6.  QiShenYiQi Pill Improves Myocardial Hypertrophy Caused by Pressure Overload in Rats.

Authors:  Shichao Lv; Qiang Wang; Meifang Wu; Meng Li; Xiaojing Wang; Ling Xu; Junping Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-16       Impact factor: 2.629

7.  The relationship between left ventricular mass and insulin resistance in obese patients.

Authors:  Cengiz Bulut; Aysen Helvaci; Mine Adas; Neslihan Ozsoy; Akif Bayyigit
Journal:  Indian Heart J       Date:  2016-01-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.